Utilization of Targeted Immune Modulators for Inflammatory Bowel Disease in Canada

Inflammatory bowel disease, a chronic gastrointestinal condition that includes Crohn disease and ulcerative colitis, is managed with various drug classes, which include targeted immune modulators such as biologics and small molecule drugs. Due to the substantial expenditures in Canada on biologic drugs and the evolving dynamics related to loss of exclusivity, the introduction of new drugs, biosimilars, and generics, as well as the availability of new evidence, there will be increasing questions regarding the appropriate sequencing of these advanced therapies. This utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.